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Abstract 
Purpose: There are no internationally agreed upon clinical guidelines as to which women with 
gynecological cancer would benefit from Lynch syndrome screening or how best to manage the risk of 
gynecological cancer in women with Lynch syndrome. The Manchester International Consensus Group 
was convened in April 2017 in order to address this unmet need. The aim of the Group was to develop 
clear and comprehensive clinical guidance regarding the management of the gynecological sequelae of 
Lynch syndrome based on existing evidence and expert opinion from medical professionals and patients.   
 
Methods: Stakeholders from Europe and North America worked together over a two-day workshop to 
achieve consensus on best practice.  
 
Results: Guidance was developed in four key areas: 1) whether women with gynecological cancer should 
be screened for Lynch syndrome and 2) how this should be done; 3) whether there was a role for 
gynecological surveillance in women with proven Lynch syndrome; and 4) what preventive measures 
should be recommended for women with Lynch syndrome to reduce their risk of gynecological cancer.   
 
Conclusion: This document provides comprehensive clinical guidance that can be referenced by both 
patients and clinicians so that women with Lynch syndrome can expect and receive appropriate 
standards of care.          
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Introduction 
Lynch syndrome is an autosomal dominant condition predisposing individuals to a constellation of 
cancers, including colorectal (CRC), endometrial (EC) and ovarian cancer (OC)1. It is caused by pathogenic 
variants of the DNA mismatch repair (MMR) system genes, MLH1, MSH2, MSH6 and PMS2, which 
prevent the correction of acquired errors during DNA synthesis. Gynecological cancers are often the 
sentinel Lynch syndrome event in women and have an excellent prognosis2. This provides an 
opportunity to diagnose women before further oncological sequelae affect them or their family. Early 
diagnosis allows women to be enrolled in cancer surveillance programs and enables cascade testing for 
at risk relatives. There is well-documented survival advantage for those with Lynch syndrome who are 
compliant with CRC surveillance3. Further, early identification of Lynch syndrome can enable the uptake 
of cancer prevention strategies, including aspirin and risk-reducing surgery4,5. A timely diagnosis may 
also have cancer prognosis and treatment implications. For example, MMR deficient tumors are 
susceptible to immune checkpoint inhibition through PD-1 blockade6. These considerations necessitate 
guidelines to direct the identification and care of individuals affected by Lynch syndrome. Although CRC 
clinical guidance is widely available, the same is not true for gynecological cancers (eTable-1). The lack of 
comprehensive guidance has led to a non-uniform approach to management of women with Lynch 
syndrome globally.  The aim of the Manchester International Consensus Meeting was to provide the first 
gynecological-specific guidance for the diagnosis, prevention and surveillance of Lynch syndrome-
associated gynecological malignancies.  
 
The Manchester International Consensus Meeting 2017 for the management of gynecological cancers 
in Lynch syndrome  
The meeting was held on 24-25th April 2017. Fifty stakeholders attended from across Europe and North 
America, including patients (n=2), patient support group representatives (n=2), gynecological oncology 
surgeons (n=12), gynecology nurse specialists (n=5), clinical geneticists (n=10), genetic counselors (n=2), 
medical oncologists (n=1), colorectal surgeons (n=2), gastroenterologists (n=1), histopathologists (n=10), 
genetic pathologists (n=1), health economists (n=1) and epidemiologists (n=1).  
 
Preparation for the meeting included a systematic review of the literature to identify key papers to 
inform discussion. A systematic review with meta-analysis was performed to provide a robust estimate 
of the prevalence of Lynch syndrome in women with endometrial cancer, using the methodology 
described in our published protocol7. The body of literature identified through this search also enabled 
informed discussion regarding the comparable utility of MMR IHC, MSI, MLH1 methylation testing and 
direct germline sequencing for pathological variants of the MMR genes by next generation sequencing, 
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for Lynch syndrome testing (eTable-2). An identical search was conducted in parallel, substituting the 
Main Subject Heading (MeSH) term ‘endometrial’ with ‘ovarian’. Further searches to identify evidence 
for risk reducing interventions and the clinical effectiveness of gynecological surveillance in Lynch 
syndrome (eTable-3) were conducted. Key studies were identified by abstract review and graded 
according to the category of evidence they achieved (Table 1). Potential bias was assessed by two 
reviewers, and discrepancies settled by a third, as previously described7; those studies with a high 
likelihood of bias were excluded. Papers identified through these searches were grouped according to 
the four clinical questions detailed in this document, and sent to the expert assigned as question lead 
before the meeting. 
  
At the meeting, day one consisted of eleven lectures covering the prevalence of Lynch syndrome and its 
associated cancer risks, the patient’s perspective, the process of developing clinical guidance, lessons 
learnt from the colorectal community, current diagnostic technologies and methods of gynecological 
surveillance. These lectures provided a critical review of the studies identified through the systematic 
searches described above and had the purpose of providing the consensus group with up to date 
evidence on which to base its recommendations. Participation was encouraged when assessing the 
quality of the available evidence during the lectures.  
 
The second day rotated delegates through working groups focused on screening for Lynch syndrome in 
gynecological cancer, diagnostic methods for such screening, the role of risk-reducing surgery and 
gynecological surveillance. Each group benefited from multidisciplinary healthcare professional and lay 
representation. Topics were debated until an agreed statement could be reached. The precise wording 
of these statements was decided through careful deliberation until unanimous agreement was 
confirmed by a show of hands. Once all delegates had rotated through the four focus groups, a final 
forum enabled group chairpersons to feed back where consensus had been reached. A further show of 
hands was required for individual statements to reach this consensus document. The document was 
written and edited by the expert writing group and circulated through all authors until each 
recommendation was ratified. The levels of recommendation are shown in Table 2. 
 
Question-1: Should women with gynecological cancer be screened for Lynch syndrome? 
 
<<Box-1>>  
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Lynch syndrome affects 1:279 of the general population, the vast majority of whom are unaware of their 
diagnosis8. Approximately 1 in 30 CRC are Lynch syndrome-associated9. The proportion of EC that are 
Lynch-syndrome associated is around 1 in 30, but estimates are based on small studies hampered by 
methodological limitations. The largest of these (n>300) are shown in eTable-2.  
 
Current UK guidance from the National Institute for Health and Care Excellence (NICE) supports the 
universal screening of CRC for Lynch syndrome10. Given similar rates of Lynch syndrome in EC and CRC, 
and the potential to reduce mortality through colorectal surveillance and cascade testing of relatives, 
the Consensus Group strongly recommends that women with EC should also be screened for Lynch 
syndrome.  
 
Restricting screening to those with a higher pre-test probability of Lynch syndrome (e.g. younger 
patients) is likely to reduce the resource burden, although at the cost of missing more Lynch syndrome 
cases. One study found only 25% of IHC MMR deficient tumors were in women <50 years11. Hampel et al 
found 20% of proven Lynch cases presented >60 years12. While older patients may have a lower risk of 
Lynch syndrome, and less potential to benefit from risk-reducing measures, they may also have younger 
relatives who could benefit from the identification of family pathogenic variants. Further, targeted 
screening has its own challenges, particularly that screening is not conducted despite being indicated. 
 
Amsterdam-II and Bethesda criteria are family history-based prediction tools designed to target Lynch 
syndrome screening in CRC. Extrapolation of these tools to EC has shown specificity of 61% and 49% for 
Amsterdam-II and Bethesda criteria, respectively13. Newer prediction tools, MMRpredict1,26, MMRpro 
and PREMM5 have increased sensitivity and specificity14-16. However, they rely on accurate family self-
reported history being recorded by the clinician, and are not validated for detecting MSH6 and PMS2 
pathogenic variant carriers17. A quality controlled family history is time consuming, outside the scope of 
many busy clinical settings and does not meet the specificity or sensitivity needed for a first line test for 
Lynch syndrome17, however, in the absence of tumor material, prediction models can be useful to guide 
germline testing for MMR pathogenic variants. 
 
Restricting Lynch syndrome screening to tumors with certain pathological phenotypes, for example 
endometrioid or clear cell morphology, tumors of the lower uterine segment, and those with heavy 
infiltrates of tumor-associated T-lymphocytes has not been tested prospectively as a means to direct 
Lynch syndrome screening18. A low BMI increases the likelihood of Lynch syndrome being the underlying 
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cause in EC19. In CRC, restricting screening for Lynch syndrome to certain high-risk pathological features 
is not sufficiently sensitive20.  
 
With regards to Lynch syndrome-associated OC, there is minimal evidence to guide clinical care. A single 
center study found 21% of non-serous epithelial OC to be MMR deficient by IHC21. Lynch syndrome-
associated OC is predominantly endometrioid, presenting at an earlier age and stage than sporadic OC, 
with improved survival rates22. Lynch syndrome is found in 7% of women with synchronous EC and OC23. 
Many professional organizations now recommend testing all epithelial OC patients for BRCA1/2 
pathological variants24,25. Given the similar cumulative risk of OC in Lynch syndrome, testing 
premenopausal women with epithelial OC for both BRCA1/2 and Lynch syndrome is appropriate. This is 
even more persuasive in an era of panel gene testing where there is no additional cost to add more 
genes.   
 
There is no evidence to support a link between Lynch syndrome and other gynecological cancers, 
neither myometrial, nor squamous cancers of the vulva, vagina or cervix, in which the most important 
etiological driver is persistent infection with high risk human papillomavirus (HPV). Thus screening for 
Lynch syndrome in women affected by cancers of the lower genital tract is not recommended, with the 
exception of (HPV independent) endocervical adenocarcinomas, given the difficulty of distinguishing 
them from lower uterine segment endometrial cancers26. 
 
 
Question-2: How should women with gynecological cancer be screened for Lynch syndrome?   
 
<<Box-2>> 
 
Screening women with gynecological cancer for Lynch syndrome is a multidisciplinary responsibility. 
Health care systems require robust procedures for quality-assured tumor testing and communication of 
results. Tissue analysis to triage women for Lynch syndrome testing highlights the potential of having 
Lynch syndrome rather than diagnosing it. Furthermore, identifying MMR defective status provides 
important prognostic information and can direct, for example, immunotherapy treatment strategies27. 
Thus, MMR IHC/MSI testing should form part of standard patient care and prior consent is not required. 
When germline testing is recommended, informed consent should be sought and patients are entitled 
to receive specialist counseling.  
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Four options were explored for the initial screening of tumor samples for Lynch syndrome: MSI, IHC with 
methylation testing, MSI with IHC and/or methylation testing and germline NGS (Figure-1). NGS is the 
gold standard for identifying somatic pathogenic variants in MMR genes; there remain challenges in 
working with formalin-fixed paraffin-embedded tumor samples, but performance of NGS on such 
samples is improving28. It should be noted that exon panel NGS will not identify MLH1 silencing due to 
methylation29. Sequencing of PMS2 is problematic due to the presence of numerous pseudogenes30. 
NGS is expensive and many hospitals have limited access to it. Thus most studies and current clinical 
practice employ a screening triage with the use of IHC and/or MSI before germline NGS and large 
rearrangement testing (eTable-2).  
 
There is good concordance between MSI and IHC analysis31,32. Where there is discordance this may, for 
example, reflect MSI secondary to POLE pathogenic variants, heterogeneity of MMR loss within the 
tumor or microsatellite stable (MSS) MSH6 or PMS2 loss32,33. The first is important because POLE 
pathogenic variants have prognostic implications; the last because MSI triage may miss Lynch syndrome 
cases due to MSH6 pathogenic variants34. For IHC, sensitivity and specificity range between 86 to 100% 
and 48-67%, respectively19,35,36. For MSI, sensitivity and specificity are similar at 77-100% and 38-
81%19,35,36. Where there is a strong family history and where EC/OC presents under the age of 50 years 
with normal IHC and/or MSI, there is still an argument for definitive NGS37. Investigations should be 
performed in an agreed stepwise and protocol-driven manner10.   
 
IHC analysis has the advantage of identifying the specific protein that has been lost, thus indicating the 
potentially mutated gene. Furthermore, some pathogenic variants in MSH6 have been shown to 
associate with tumor MSS38. The identification of MLH1 protein loss enables methylation analysis, which 
can exclude women with somatic MLH1 loss from unnecessary NGS38. Methylation-specific PCR is simple 
and cost effective, however validation work has been almost exclusively in the CRC population39,40. 
Methylation-specific PCR is not widely available, with only specialist laboratories offering this test. The 
molecular mechanism for the strong association of BRAF mutation with CRC harboring somatic MLH1 
hypermethylation is incompletely understood but appears to be tissue/tumor-specific; unlike algorithms 
in use for CRC, BRAF immunohistochemistry or sequencing cannot be used as a proxy for 
somatic MLH1 hypermethylation in gynecological cancers, as oncogenic BRAF mutations occur so rarely 
in these41.  Therefore, moving straight to germline NGS on the basis of IHC MLH1 loss is also an option, 
although an expensive one.    
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The MMR proteins form heterodimers, with MLH1 pairing with PMS2 and MSH2 pairing with MSH6. 
These proteins are unstable in their unpaired state, and while MLH1 and MSH2 can form stable 
heterodimers with other proteins, PMS2 and MSH6 can only dimerise with MLH1 and MSH2 
respectively. It has therefore been proposed that IHC analysis can be performed by testing only two of 
the four MMR proteins, PMS2 and MSH6, because loss of MLH1 and MSH2 leads to loss of their 
heterodimer partner (PMS2 and MSH6 respectively)42. However, the accuracy of this system is unproven 
in gynecological cancers43. The interpretation of stained slides requires an experienced senior clinician, 
and IHC more frequently needs to be repeated due to uninterpretable staining patterns in EC compared 
to CRC44. Furthermore, the effect of neoadjuvant treatment on tissue analysis for MMR dysfunction has 
not been defined in EC45. A reporting proforma is shown in eFigure-1. The continuing use of tightly-
regulated and high quality IHC protocols should be assured by laboratory participation in a national or 
international external quality assurance scheme that covers both IHC methods and interpretation.    
 
A testing strategy using IHC and MLH1 methylation is likely to be more cost-effective than strategies 
using MSI testing (since MLH1 methylation must be conducted on all MSI tumors) and strategies not 
using MLH1 methylation (since methylation testing is cheaper than NGS and excludes a significant 
proportion of sporadic cases). Documented IHC results can also help interpret NGS results. 
 
Question-3: Is there a role for gynecological surveillance in women with proven Lynch syndrome? 
 
<<Box-3>> 
 
Many Lynch syndrome women opt to undergo gynecological surveillance in lieu of, or whilst awaiting 
risk-reducing surgery. The aim of surveillance is to detect premalignant disease or early stage cancer, 
with the ultimate aim of improving morbidity and mortality from the malignant gynecological sequelae 
of Lynch syndrome.  
 
The data relating to gynecological surveillance in Lynch syndrome are generally of low quality, with 
single center, retrospective studies predominating (eTable-3). Some studies show benefit and others 
show no benefit of gynecological surveillance in the early detection of endometrial cancer in Lynch 
syndrome46. Survival data are limited and mortality data are lacking. However, both pre-invasive 
(atypical hyperplasia) and stage 1 disease have been diagnosed in asymptomatic women undergoing EC 
surveillance (eTable-3). One study found that women who were not under surveillance were more likely 
to die from their EC than those in surveillance, although this did not reach statistical significance. In 
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addition, three cancers were ‘missed’ in the surveillance group47. Another found a high proportion of 
interval ECs in women undergoing surveillance (6/13)48. It is important to note that EC survival rates in 
women with Lynch syndrome are extremely good, with 10-year survival of 98% in those undergoing 
surveillance3; comparative data for LS-EC in women not undergoing surveillance are not available. 
 
The Consensus Group acknowledged that ultrasonography, biopsy and hysteroscopy could detect EC 
and premalignant pathological abnormalities. However, there is no evidence that this leads to a stage 
shift or improved survival in women with Lynch syndrome-associated EC. Furthermore, many patients 
identified during gynecological surveillance are symptomatic of endometrial pathology (eTable-3). 
Patient representatives in the Group were strong advocates of gynecological surveillance as a means of 
regular review and reassurance. Therefore the Consensus Group supported a discussion with individual 
women as to whether they would wish an annual appointment to undergo detailed symptom enquiry, a 
re-discussion regarding the option for risk-reducing hysterectomy and bilateral salpingo-oophorectomy 
and the timing of this, as well as a holistic review of a woman’s contraceptive and fertility needs, and 
advice regarding cancer risk-reducing behaviors.  Women with red flag symptoms of gynecological 
cancer, including abnormal bleeding, weight loss, bloating, change in bowel habit, recurrent urinary 
symptoms and abdominal pain should undergo targeted investigations for gynecological pathology49,50. 
The Consensus Group were strongly supportive of the need for rapid access facilities being available for 
women with Lynch syndrome and that suspicious symptoms or signs of malignant gynecological disease 
should not await routine review in clinic.  
 
Regarding OC, there is currently insufficient evidence that surveillance is of benefit46. Large RCTs of 
general population screening for OC through ultrasound scanning (USS) or multimodal screening (CA125 
analyzed by an algorithm as a first line test, followed by reflex USS) have so far failed to demonstrate a 
statistically significant mortality benefit51,52. However, screening in high-risk BRCA1/2 pathogenic variant 
carriers with 4-monthly CA125 analyzed by an algorithm and reflex USS does lead to a stage-shift in the 
disease detected; whether this translates into mortality benefit has yet to be established53. 
Extrapolation of OC screening research to the LS population is limited by the known biological 
differences between LS-associated and sporadic/BRCA1/2-associated OC54. 
 
Whilst there is true equipoise in the literature, high quality research regarding the value of gynecological 
surveillance in Lynch syndrome could be performed. The options for study design could include a cluster 
RCT or a centralized repository for routine data collection from local surveillance programs. Studies 
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should be adequately powered to determine whether surveillance picks up earlier disease with benefits 
for patient outcomes, as well as assessing its psychological impact and cost effectiveness.  
 
Question-4: What preventive measures should be recommended for women with Lynch syndrome to 
reduce their risk of gynecological cancer? 
 
<<Box-4>>  
 
Risk-reducing total hysterectomy and bilateral salpingo-oophorectomy prevents gynecological cancer in 
women with Lynch syndrome5. Surgery is not without risk and potential long-term side effects, however, 
and pre-operative counseling is important. The laparoscopic approach is associated with less 
postoperative pain, quicker recovery and improved short-term quality of life, making it the preferred 
approach in uncomplicated cases, where resources permit55. Surgical menopause follows risk-reducing 
oophorectomy in premenopausal women. This is associated with vasomotor symptoms, urogenital 
dryness and atrophy, reduced sexual function, emotional lability and cognitive decline, as well as 
increased risks of osteoporosis, cardiovascular disease and CRC56. Thus prescription of estrogen-only 
HRT until at least natural menopause age (~51-years) is strongly recommended to prevent these 
sequelae. There is some evidence that prior hysterectomy may be associated with greater discomfort 
during intubation at colonoscopy, and lower cecal intubation rates57  Thus it has been suggested that 
women undergoing colonoscopic surveillance following hysterectomy undergo specific pre-procedure 
counseling and measures to reduce procedural discomfort58. 
 
There are good quality prospective data outlining the cancer risk associated with specific pathogenic 
variants and the age at which these occur59 woman’s personal risk should be used to provide 
individualized counseling regarding the need for risk-reducing surgery and the optimal timing of this. 
According to the Prospective Lynch Syndrome Database (PLSD-http://www.lscarisk.org), the lifetime risk 
of EC in women with MSH2, MLH1 and MSH6 pathogenic variants is 57%, 43% and 46%, 
respectively. The cumulative risk of EC at 40 years of age is 2%, 3% and 0%, respectively. Lifetime risk for 
OC in women with MSH2, MLH1 and MSH6 pathogenic variants is 17%, 10% and 13%, respectively.  The 
cumulative risk of OC at 40 years of age is 4%, 3% and 4%, respectively59. Thus MSH6 pathogenic variant 
carriers may consider undergoing risk-reducing surgery after the age of 40 years, while women with 
pathogenic variants in either MSH2 or MLH1 may consider risk-reducing surgery at around 35 years of 
age assuming their childbearing is complete60. Risk-reducing surgery at 40 years of age is a cost-effective 
strategy61. The risk of gynecological cancer in PMS2 carriers is low; however, patient representatives 
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with PMS2 pathogenic variants felt strongly that they should be offered risk-reducing surgery alongside 
other women with Lynch syndrome59.     
 
There is limited evidence as to how reproductive and lifestyle factors impact on gynecological cancer 
risk in women with Lynch syndrome. One study suggested that hormonal influences do modulate cancer 
risk, however. In addition to combined oral contraceptives, progestin-only methods (pills, injectable, 
implants or intrauterine system, IUS) may protect, but there is little supporting evidence62. The POET 
trial looked to explore the use of the IUS for the prevention of EC in women with Lynch syndrome. This 
trial closed due to poor recruitment without results. Another study showed an anti-proliferative effect 
of exogenous progesterone on the endometrium of women with Lynch syndrome, suggesting that these 
agents could be useful for the chemoprevention of EC63. Exogenous hormones may also protect against 
CRC64.  
 
Aspirin reduces incidence of Lynch syndrome-associated EC and other cancers65. The main toxic effects 
of aspirin are gastrointestinal. Major gastrointestinal bleeds (those requiring transfusion) are increased 
in aspirin-takers with an OR of 1.5-266. However, the absolute rates are small and mainly affect older 
individuals. Since gastrointestinal toxicity is dose dependent, the optimal dose for cancer risk reduction 
is being explored through the CaPP3 study of 100mg, 300mg or 600mg/day (http://www.capp3.org/).  
 
Smoking, alcohol use and increased body mass index may increase the risk of CRC in individuals with 
Lynch syndrome, however the impact of lifestyle factors on gynecological cancer risk is unknown. Aspirin 
may ‘normalize’ EC risk in obese women with Lynch syndrome67. Despite lack of robust evidence, Lynch 
syndrome women are advised to eat a healthy diet, avoid obesity, take regular exercise, avoid smoking, 
only drink alcohol in moderation, and avoid known carcinogens as part of maintaining healthy lifestyles. 
 
Discussion 
This is the first gynecology-focused internationally agreed clinical guideline for the care of women with 
Lynch syndrome.  
 
Our key recommendations are as follows: 1)-All stakeholders should be informed of the impact of Lynch 
syndrome on gynecological cancer risk; 2)-Systems should be established to screen for Lynch syndrome 
in women with endometrial cancer; 3)-Women with Lynch syndrome should be offered risk-reducing 
hysterectomy with bilateral salpingo-oophorectomy, at a time appropriate to them; and 4)-Further 
research is required to establish the value of gynecological cancer surveillance in women with Lynch 
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syndrome and to explore other key areas where there is currently deficient evidence to define 
appropriate standards of care. Screening for Lynch syndrome is only recommended if effective 
management exists to benefit those who screen positive.   
 
The strength of our guidance comes from the broad and expert medical specialty representation that 
forms our Consensus Group. All relevant stakeholders, including patients and patient advocates were 
given equal voice during discussion. Despite different perspectives and expertise, we were able to 
achieve a consensus view on topics of international importance. By focusing solely on the gynecological 
aspects of Lynch syndrome, we were able to provide the most comprehensive guidelines yet for the 
empowerment of both clinicians and patients. This was all achieved without corporate sponsorship.  
 
The major limitation of our work is the lack of robust evidence on which to base our discussions and 
recommendations. It is hoped that these guidelines will provide the much-needed impetus to inspire 
researchers and funders to undertake and commission high quality research to fill these gaps in our 
understanding.   
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Table 1. Grading of evidence 
 
Grading of Evidence  
Category of Evidence  Grading of evidence  
  Traditional Guideline  
Meta-analysis of randomized control trials Ia A 
Randomized control trials Ib A 
Well designed and controlled study without randomization  IIa B 
Well-designed quasi-experimental study IIb B 
Non-experimental descriptive study III B 
Expert opinion  IV C 
 
 
 
Table 2. Levels of recommendation 
 
Level Description  Rationale 
Strongly 
recommend 
Patients should expect this level of 
care 
Unanimous agreement from the consensus 
members. Level of evidence is thought to be 
sufficient to make this recommendation  
Recommend Care providers and stakeholders 
should aim to provide this level of 
care 
Unanimous agreement from the consensus 
members. Level of evidence is supports the 
recommendation but is not conclusive 
Neutral  Care providers and stakeholders may 
wish to provide this service  
No unanimous agreement and evidence 
inconclusive.   
 
 
 
Box-1. Consensus recommendations for screening women with gynecological cancer for Lynch 
syndrome 
 
Where resources are available, the Consensus Group strongly recommends universal screening of 
endometrial cancer for Lynch syndrome (Grade B).  
 
Where resources are restricted, the Consensus Group strongly recommends screening for Lynch 
syndrome in endometrial cancer where  
• women are diagnosed at 60 years of age or younger (Grade B). 
• women diagnosed at any age have one or more of the following risk factors: a personal history 
of metachronous or synchronous Lynch syndrome-associated cancer; a first degree relative with Lynch 
syndrome-associated cancer at 60 years of age or younger;  pathological features strongly suggestive of 
a Lynch syndrome-associated cancer (Grade B). 
 
The Consensus Group recommends screening for Lynch syndrome in ovarian cancer where 
• women are diagnosed at 50 years of age or younger (Grade C). 
• women diagnosed at any age have non-serous and non-mucinous histology (Grade C). 
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Box-2. Consensus recommendations for the methodology used to screen women with gynecological 
cancer for Lynch syndrome 
 
The Consensus Group strongly recommends that quality assured processes for the identification, 
screening and reporting of tests for Lynch syndrome are piloted and audited before they are 
implemented at a local level (Grade B). 
 
The Consensus Group strongly recommends that tumor MMR or MSI status is used to identify women 
for germline Lynch syndrome testing. There is no evidence to advocate MSI over MMR 
immunohistochemistry or vice versa. (Grade B). 
 
Where MMR immunohistochemistry is performed, the Consensus Group recommends testing for all four 
MMR proteins using formalin-fixed paraffin-embedded biopsy or resected tumor specimens (Grade B).  
 
The Consensus Group strongly recommends that immunohistochemistry testing is tightly regulated and 
protocol-driven to ensure interpretable, quality-assured results that can be understood by non-specialist 
clinicians (Grade C).  
 
Where MLH1 protein loss is identified or initial screen suggests MSI-H, the Consensus Group 
recommends the use of promoter methylation-specific PCR to identify probable cases of MLH1 silencing 
and therefore further filter the number of samples requiring NGS, while noting that a small proportion 
of such cases are due to constitutional methylation or pathogenic variants involving MLH1  (Grade B). 
BRAF immunohistochemistry or sequencing cannot be used as a proxy for somatic MLH1 
hypermethylation in gynecological cancers  (Grade B).  
    
For ovarian cancer, the Consensus Group strongly recommends somatic NGS on formalin-fixed paraffin-
embedded or fresh frozen tumor tissue of non-mucinous invasive epithelial tumors, which should 
include BRCA1/2 and Lynch syndrome genes (Grade B/C).  
      
The Consensus Group strongly recommends that explicit patient consent is sought before germline 
testing (Grade C).  
 
The Consensus Group strongly recommends appropriate referral pathways are established with Clinical 
Genetics before screening is initiated. This includes those with a positive triage test who are negative for 
a germline Lynch syndrome pathogenic variant (Grade B/C).  
 
Where tumor tests suggest Lynch syndrome but there is no Lynch syndrome-associated pathogenic 
variant on germline NGS, the Consensus Group recommends that clinicians seek to establish the 
existence of other somatic or germline pathogenic variants, such as biallelic MuTYH, POLE and/or double 
somatic MMR pathogenic variants, which may have prognostic implications (Grade B).  
 
All recommendations are based on current technology. As this evolves so should clinical practice.   
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Box-3. Consensus recommendations for gynecological surveillance in women with proven Lynch 
syndrome 
 
The Consensus Group strongly recommends that all women with proven Lynch syndrome be informed of 
their pathogenic variant-specific risk of gynecological cancer, specifically endometrial and ovarian 
cancer, interpreted in the context of their family history (Grade C). 
 
The Consensus Group recommends that women with proven Lynch syndrome who have not experienced 
gynecological cancer undergo optional annual review from the age of 25 with an appropriate clinician to 
discuss red flag symptoms for endometrial and ovarian cancer*, and where contraceptive and fertility 
needs are raised. A gynecological referral should be made if there is a specific need (Grade C).  
 
The Consensus Group does not recommend invasive gynecological surveillance in Lynch syndrome 
(Grade C), due to insufficient evidence that this improves outcomes over symptom awareness and 
urgent investigation of red flag symptoms. The Consensus Group strongly recommends further research 
in this area be prioritized by funding bodies. Furthermore, where good quality endometrial cancer 
surveillance programs already exist, systematic collection of cancer outcomes should be undertaken.  
 
The Consensus Group strongly recommends that women participate in routine cervical screening in line 
with local cervical screening programs (Grade A). 
 
 
* Red flag symptoms of gynecological cancer include abnormal bleeding, weight loss, bloating, change in 
bowel habit, recurrent urinary symptoms and abdominal pain50. 
 
 
 
Box-4. Consensus recommendations for gynecological cancer risk reduction in women with known 
Lynch syndrome  
 
The Consensus Group strongly recommends that risk-reducing total hysterectomy and bilateral salpingo-
oophorectomy is offered no earlier than 35-40 years of age following completion of childbearing, in 
proven MLH1, MSH2 and MSH6 pathogenic variant carriers (Grade B). A woman’s personal risk should 
be used to provide individualized counseling regarding optimal timing of the procedure. The strength of 
evidence is insufficient to strongly recommend risk-reducing surgery in PMS2 pathogenic variant 
carriers.  
 
The Consensus Group strongly recommends high quality pre-operative multidisciplinary counseling 
supplemented by patient-friendly written information regarding the risks and benefits of risk-reducing 
surgery (Grade C).  
 
The Consensus Group recommends pre-operative endometrial biopsy and pelvic ultrasound to identify 
occult gynecological cancer, particularly if a woman is symptomatic (Grade C).  
 
The Consensus Group strongly recommends that women who are not up-to-date with colorectal 
surveillance are offered colonoscopy at the time of their risk-reducing surgery (Grade B).  
 
The Consensus Group recommends that surgery is offered at specialist surgical center, although women 
at low surgical risk should be able to choose local care (Grade C).  
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The Consensus Group strongly recommends all pathological assessment and reporting is carried out at a 
specialist gynecological pathology center and that the entire endometrium is sampled in the case of 
prophylactic hysterectomy. (Grade C).  
 
The Consensus Group strongly recommends that women who undergo risk-reducing hysterectomy and 
removal of their ovaries are offered estrogen-only hormone replacement therapy (HRT) (preferably via 
the transdermal route) until the natural age of the menopause (age 51 years) or, in consultation with 
their specialist, until they wish to stop.  (Grade B).  
 
The Consensus Group recommends that risk-reducing colorectal and gynecological surgery are carried 
out at the same time, when indicated and where possible (Grade C).*  
 
The Consensus Group recommends that surgery for colorectal cancer and risk-reducing hysterectomy 
are carried out at the same time, when indicated and where possible (Grade C).  
 
Where risk-reducing surgery has been declined or is not yet appropriate, the Consensus Group 
recommends women with Lynch syndrome are given the opportunity to discuss their fertility and 
contraceptive needs with a specialist (Grade C).  
 
The Consensus Group recommends that the combined oral contraceptive pill is considered for women 
with Lynch syndrome and wishing contraception because it reduces endometrial and ovarian cancer risk 
(Grade B).  
 
The Consensus Group strongly recommends that women with Lynch syndrome take aspirin 
chemoprevention to reduce their risk of colorectal and other cancers (Grade A), within the context of a 
clinical trial (e.g. CaPP3), or through discussion with their doctor.  
   
The Consensus Group recommends that women with Lynch syndrome maintain a healthy body mass 
index (BMI) (Grade B).   
 
The Consensus Group recommends that women with Lynch syndrome eat a healthy diet, take regular 
exercise, do not smoke cigarettes, drink alcohol in moderation or not at all, and avoid known 
carcinogens (e.g. tamoxifen) as part of maintaining a healthy lifestyle (Grade B).   
 
 
* Risk-reducing colorectal surgery here refers to an extended colectomy at the time of a colorectal 
cancer or in the event of any other benign indication for a colonic resection such a multiple (right-sided) 
recurrent polyps. 
 
